NL-OMON54169招募中不适用
Clinical evaluation of Contrast Enhanced Breast CT to improve Staging and treatment follow up in women with breast cancer - CEBCT vs MR
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 413
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Women >18 years old
- •- Diagnoses of breast cancer
- •- Scheduled for a pre-surgery staging contrast enhanced breast MRI
- •- Eligible for primary systemic therapy
排除标准
- •- Women with suspected or confirmed pregnancy
- •- Women with prior breast cancer
- •- Women who are breastfeeding
- •- Women who are very frail and unable to cooperate
- •- Women who cannot give informed consent
- •- Contra indication of iodine contrast
- •- Contra indication for irradiation (i.e. genetic mutation that predispose to
- •breast cancer)
- •- Male subjects
研究者
相似试验
尚未招募
不适用
Clinical evaluation of Contrast Enhanced Breast CT in women recalled from screening due to calcificationsMamma calcifications10006291breast cancerNL-OMON56633Radboud Universitair Medisch Centrum539
已完成
不适用
Clinical study of contrast-enhanced mammography on pre-operative diagnosis of breast cancerBreast cancerJPRN-UMIN000026800Dokkyo Medical University Koshigaya Hospital50
已完成
不适用
Evaluation of the usefulness of breast CT imaging in delineating tumor extent and guiding surgical management: a prospective multi-institutional studybreast cancerJPRN-UMIN000005029Grants for Scientific Research from the Expenses for Health and Welfare Program (17-7) from the Ministry of Health, Labour and Welfare of Japan300
尚未招募
不适用
Evaluation of Contrast Enhanced Breast CT for Diagnosis and Staging of Breast CancerBreast CancerNCT05404087Radboud University Medical Center413
进行中（未招募）
1 期
Evaluation of the use of contrast agent in mammography to improve the specificity of breast cancer diagnosisPatients with breast lesions undergoing further examinationMedDRA version: 20.0Level: PTClassification code 10061021Term: Breast disorderSystem Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2019-000326-22-ITISTITUTO EUROPEO DI ONCOLOGIA170